The Inquisitor: New setbacks leave Elan even more vulnerable
The firm has been hit by the failure of its latest Alzheimer drug trials, and the imminent departure of Kelly Martin as chief executive, writes Richard Curran.
Robert Ingram, the chairman of Elan, told shareholders last March that group chief executive Kelly Martin would be staying on until data from trials of its potential new Alzheimer's treatment Bapineuzumab were made available.
Ingram said the drug was potentially of "transformational significance" for the company. Last week's disappointing results, which saw it fail to get through clinical trials, may well end up being transformational for Elan, but not in the way Ingram had in...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
The year in review
The best writing and and the biggest stories of 2019 from the Business Post
Newsround: What Thursday’s papers say
Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals
More cycle routes, expansion of Luas to Bray and new bus network proposed
Greater Dublin Area draft Transport Strategy published
